Bridgewater (BWB) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Quince Therapeutics is advancing eDSP for Ataxia-Telangiectasia, leveraging strong prior data in the 6-9 age group and an innovative AIDE platform. Recent insider buying, new analyst coverage with high price targets, and robust patent protection highlight growing confidence and upside potential. Data readout for the NEAT Phase 3 trial is scheduled for early 2026, with all patients joining the open-label extension, and cash runway aligns with expected topline results.

If you are looking for stocks that are well positioned to maintain their recent uptrend, Life360 (LIF) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Over approximately the last three weeks, markets have been on the rise big-time. The S&P 500 closed just under $5,900 on May 14, just around 4% lower than the all-time high it reached in February.

VIENNA , May 15, 2025 /PRNewswire/ -- uCloudlink (NASDAQ: UCL), the world's first and leading mobile data traffic-sharing marketplace, made its debut at MVNOs World 2025. On May 14, uCloudlink Brand Ambassador Matthias delivered a keynote speech titled "Innovations for: NEW REVENUE, BEST NETWORK, LOYALTY RETENTION," unveiling groundbreaking solutions designed to empower MVNOs and MNOs.

Advanced Micro Devices, Inc. remains undervalued at 18x 2026 EPS, with strong AI prospects and a recent 60% rebound from lows. Blockbuster Q1 earnings beat expectations, with AI sales up 57% YoY and client segment sales up 68%. Major $10B AI partnership with HUMAIN and a $6B buyback boost long-term growth and EPS potential.

Following the approval, ABBV's Emrelis becomes the first FDA-approved therapy for previously treated advanced NSCLC patients with high c-Met protein overexpression.

For investors seeking momentum, Simplify Interest Rate Hedge ETF PFIX is probably on the radar. The fund just hit a 52-week high and has moved up 63% from its 52-week low of $37.00 per share.

24/7 Wall St.

NEW YORK, NY / ACCESS Newswire / May 15, 2025 / If you suffered a loss on your Digimarc Corporation (NASDAQ:DMRC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/digimarc-corporation-lawsuit-submission-form-2?prid=148681&wire=1&utm_campaign=1 or contact Joseph E. Levi, Esq.

Tiziana Life Sciences Ltd (NASDAQ:TLSA)' investigational therapy intranasal foralumab has been shown to significantly reduce neuroinflammation in a 78-year-old patient with moderate Alzheimer's disease (AD), a newly published study has shown. The study, published in the Journal of Clinical Nuclear Medicine, was led by Dr Tarun Singhal and Dr Howard Weiner of Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system.

The P/B ratio helps to identify low-priced stocks with high growth prospects. CNC, CVS, PFE, STNE and SAN are some such stocks.

Investors interested in LMT stock should wait for a better entry point, considering its higher debt-to-capital ratio.

BA receives an order from AviLease to deliver up to 30 737-8 commercial aircraft.

AEM currently holds 39,125,448 common shares of Foran Mining, representing about 9.9% of the total outstanding shares on an undiluted basis.

LDOS makes a strong case for investment in the aerospace-defense industry, given its solid earnings growth prospects, rising backlog and shareholder-friendly initiatives.

STERIS' fourth-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues.

Despite the mixed Q4 earnings and underperformance caused by Family Dollar in recent years, Dollar Tree still has respectable financials and growth potential. Dollar Tree is well-positioned to recover following the divestiture of Family Dollar for $1.007 billion, increasing profitability and significantly reducing operating costs while growing its flagship stores. The company plans to expand its Multi-Price Strategy from 2900 to 5200 store locations by the end of 2025, increasing its customer base and mitigating the effects of Trump's tariffs.

Battered and bruised through Q1, the Magnificent Seven and other large- and mega-cap growth stocks have facilitated the broader market's recent bullishness.

BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the pricing of an underwritten public offering consisting of (i) 11,735,565 shares of its common stock and accompanying warrants to purchase an aggregate of 2,933,891 shares of common stock and (ii) to certain investors, pre-funded warrants to purchase an aggregate of up to 3,571,435 shares of its common stock at an exercise price of $0.00001 per pre-funded warrant, and accompanying warrants to purchase up to 892,858 shares of its common …